IL-17RB recruits TRAF6, activates NF-kB, upregulates Bcl-2, and induces resistance to etoposide. IL-17RB or IL-17B targeting with Abs attenuates human MDA-MB361 breast cancer cell colony formation in vitro and tumor growth in vivo. Here, BCL2 is linked to breast carcinoma.